Unlock instant, AI-driven research and patent intelligence for your innovation.
Modifier of 5-HT2A serotonin receptor
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A halogen, solvate technology, applied in the field of regulators of 5-HT2A serotonin receptors
Inactive Publication Date: 2013-11-20
ARENA PHARMA
View PDF10 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Both have antipsychotic effects, but the typical treatments described also include concomitant motor-related side effects (extrapyramidal syndromes such as lip twitches, tongue twitches, locomotion movements, etc.)
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
preparation example Construction
[0489] for the active content of 125 The synthetic method that I incorporates target molecule comprises:
[0490] A. Sandmeyer and similar reactions - this procedure converts an aryl or heteroaryl amine to a diazonium salt such as tetrafluoroborate and then uses Na 125 I converted to 125 I labeled compound. A representative procedure is reported by Zhu, D.-G. and co-workers in J. Org. Chem. 2002, 67, 943-948.
[0491] B. Phenol ortho 125 Iodination - This procedure allows 125 I was incorporated in the ortho position to the phenol as reported by Collier, T.L. and coworkers in J. labeled Compd Radiopharm. 1999, 42, S264-S266.
[0492] C. Aryl bromides and heteroaryl bromides with 125 I Interchange - This method is usually a two-step procedure. The first step is to use such as Pd to catalyze the reaction [ie Pd(Ph 3 P) 4 ] or via aryllithium or heteroaryllithium in a trialkyltin halide or hexaalkylditin [e.g., (CH 3 ) 3 SnSn(CH 3 ) 3 ] to convert aryl and heteroaryl ...
example 1
[0498] Example 1: Synthesis of Compounds of the Invention.
[0499] Exemplary syntheses of compounds of the invention are shown in Figures 1 to 8 , where the symbols used have the same definitions throughout this disclosure.
[0500] The compounds of the invention and their synthesis are further illustrated by the following examples. The following examples are provided to further define the invention without, however, limiting the invention to the details of these examples. Compounds described herein above and below are named according to CS Chem Draw Ultra version 7.0.1 or AutoNom2000. Common names are used in certain instances and it is understood that those skilled in the art will recognize these common names.
[0501] Chemical Properties: Proton NMR ( 1 H NMR) spectra were obtained on a Varian Mercury Vx-400 equipped with 4-nuclear autotransfer probe and z-gradient or Bruker Avance equipped with QNP (Quad nuclear probe) or BBI (broadband inverse probe) and z-gradient ...
example 11
[0504] Example 1.1: Preparation of N-{3-(4-chloro-2-methyl-2H-pyrazol-3-yl)-4-[2-(1-methyl-piperidin-4-ylamino)-ethyl Oxy]-phenyl}-3-trifluoromethyl-benzamide (compound 45).
[0505] To N-(4-(2-bromo-ethoxy)-3-(4-chloro-2-methyl-2H-pyrazol-3-yl)phenyl)-3-trifluoromethyl-benzyl To a solution of amide (0.050 g, 99.5 μmol) in DMA (3 mL) was added 1-methyl-piperidin-4-ylamine (17.0 mg, 149 μmol) and N,N-diisopropylethylamine (34.7 μL, 199 μmol). The reaction mixture was heated at 150° C. for 30 minutes in a thick-walled sealed tube under microwaveirradiation and then purified by preparative HPLC. The corresponding fractions were collected and lyophilized to afford the diTFA salt of the title compound (hygroscopic) as a white solid in 40.1% yield. LCMS m / z(%)=536(M+H, 35 Cl,100),538(M+H, 37 Cl, 43). 1 H NMR (400MHz, DMSO-d 6 )δ10.56(s,1H),9.11-8.92(m,2H),8.31-8.24(m,2H),8.01-7.95(m,2H),7.80(t,J=7.8Hz,1H),7.73 (d,J=2.6Hz,1H),7.71(s,1H),7.31(d,J=9.1Hz,1H),4.37-4.23(m,2H),3.6...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotoninreceptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT2A serotoninreceptor associated disorders in combination with other pharmaceutical agents administered separately or together.
Description
[0001] This application is a divisional application of an invention patent application with an application date of May 17, 2007, an application number of 200780014847.3, and an invention title of "modulator of 5-HT2A serotonin receptors". technical field [0002] The present invention is about regulating 5-HT 2A Certain compounds of formula (Ia) with serotonin receptor activity and pharmaceutical compositions thereof. The compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or its symptoms, anxiety or its symptoms, behavioral disturbance, drug-induced psychosis, excitatory psychosis, Gilles de la Tourette syndrome, manic psychosis, organic or NOS psychosis, mental disorder, psychosis , acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders,...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.